NYSE:EBS Emergent BioSolutions - EBS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Emergent BioSolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $14.10 +0.41 (+2.99%) (As of 02/7/2023 12:00 AM ET) Add Compare Share Share Today's Range$13.47▼$14.1250-Day Range$11.00▼$14.5552-Week Range$10.61▼$47.71Volume683,522 shsAverage Volume779,092 shsMarket Capitalization$703.45 millionP/E Ratio18.08Dividend YieldN/APrice Target$36.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Emergent BioSolutions MarketRank™ ForecastAnalyst RatingHold2.17 Rating ScoreUpside/Downside160.6% Upside$36.75 Price TargetShort InterestBearish13.21% of Float Sold ShortDividend StrengthN/ASustainability-1.40Upright™ Environmental ScoreNews Sentiment0.66Based on 13 Articles This WeekInsider TradingSelling Shares$22,829 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.73) to $0.39 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.79 out of 5 starsMedical Sector43rd out of 1,029 stocksPharmaceutical Preparations Industry16th out of 504 stocks 3.1 Analyst's Opinion Consensus RatingEmergent BioSolutions has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.75, Emergent BioSolutions has a forecasted upside of 160.6% from its current price of $14.10.Amount of Analyst CoverageEmergent BioSolutions has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.21% of the float of Emergent BioSolutions has been sold short.Short Interest Ratio / Days to CoverEmergent BioSolutions has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Emergent BioSolutions has recently decreased by 3.77%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEmergent BioSolutions does not currently pay a dividend.Dividend GrowthEmergent BioSolutions does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEmergent BioSolutions has received a 73.60% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Influenza vaccines", "Cholera vaccines", and "Antibiotics" products. See details.Environmental SustainabilityThe Environmental Impact score for Emergent BioSolutions is -1.40. Previous Next 3.7 News and Social Media Coverage News SentimentEmergent BioSolutions has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Emergent BioSolutions this week, compared to 3 articles on an average week.Search Interest8 people have searched for EBS on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Emergent BioSolutions to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Emergent BioSolutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,829.00 in company stock.Percentage Held by Insiders11.10% of the stock of Emergent BioSolutions is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.44% of the stock of Emergent BioSolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Emergent BioSolutions are expected to grow in the coming year, from ($1.73) to $0.39 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Emergent BioSolutions is 18.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.77.Price to Earnings Ratio vs. SectorThe P/E ratio of Emergent BioSolutions is 18.08, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 106.28.Price to Book Value per Share RatioEmergent BioSolutions has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Emergent BioSolutions (NYSE:EBS) StockEmergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.Read More Receive EBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter. Email Address EBS Stock News HeadlinesJanuary 18, 2023 | marketbeat.comJohnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock? (EBS)Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.February 7, 2023 | americanbankingnews.comFY2022 EPS Estimates for Emergent BioSolutions Inc. (NYSE:EBS) Reduced by AnalystFebruary 7, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…February 6, 2023 | finance.yahoo.comEmergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023February 5, 2023 | finance.yahoo.comEmergent BioSolutions Inc.'s (NYSE:EBS) Intrinsic Value Is Potentially 73% Above Its Share PriceJanuary 26, 2023 | finance.yahoo.comFDA identifies recall of Emergent's decontamination kits as most seriousJanuary 26, 2023 | finance.yahoo.comUPDATE 1-FDA identifies recall of Emergent's decontamination kits as most seriousJanuary 10, 2023 | finance.yahoo.comU.S. FDA panel to review Emergent's OTC opioid overdose drugFebruary 7, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 10, 2023 | finance.yahoo.comEmergent (EBS) to Start Restructuring Plan, Lays Off 5% WorkforceJanuary 9, 2023 | finance.yahoo.comEmergent BioSolutions initiates layoffs, leadership and structural changes to cut costsJanuary 9, 2023 | markets.businessinsider.comEmergent BioSolutions Reports Prelim. 2022 Results; Announces Organizational ChangesJanuary 9, 2023 | reuters.comEmergent BioSolutions to reduce workforce by about 5%January 9, 2023 | finance.yahoo.comEmergent BioSolutions to cut 5% of its workforce in reorganization effortJanuary 8, 2023 | finance.yahoo.comEmergent BioSolutions Inc. (EBS)January 5, 2023 | finance.yahoo.comEmergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of DefenseJanuary 5, 2023 | finance.yahoo.comEmergent BioSolutions gets new Defense Department contract, shares rise 13%December 26, 2022 | finance.yahoo.comShareholders in Emergent BioSolutions (NYSE:EBS) are in the red if they invested three years agoDecember 12, 2022 | finance.yahoo.comDurham drugmaker to cut workforce by 25%, focus on new cancer drugDecember 8, 2022 | finance.yahoo.comWhy Is Emergent Biosolutions (EBS) Down 3.7% Since Last Earnings Report?December 7, 2022 | seekingalpha.comEmergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent DevelopmentsDecember 6, 2022 | finance.yahoo.comEmergent earns fast-track review for selling opioid overdose drug without prescriptionDecember 6, 2022 | finance.yahoo.comNarcan Maker Gets Fast-Tracked for Over-the-Counter Nasal SprayDecember 6, 2022 | finance.yahoo.comEmergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal SprayDecember 6, 2022 | finance.yahoo.comFDA to review Emergent's request to approve over-the-counter NarcanDecember 1, 2022 | finance.yahoo.comZacks.com featured highlights include Emergent Biosolutions, Western Digital, Thoughtworks Holding and DASAN Zhone Solutions.November 14, 2022 | finance.yahoo.comEmergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided ApproachSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter. Email Address EBS Company Calendar Last Earnings11/04/2021Today2/07/2023Next Earnings (Confirmed)2/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNYSE:EBS CUSIP29089Q10 CIK1367644 Webwww.emergentbiosolutions.com Phone(240) 631-3200Fax301-795-1899Employees2,416Year FoundedN/APrice Target and Rating Average Stock Price Forecast$36.75 High Stock Price Forecast$55.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+160.6%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.78 Trailing P/E Ratio18.08 Forward P/E RatioN/A P/E GrowthN/ANet Income$230.90 million Net Margins3.54% Pretax Margin7.73% Return on Equity9.52% Return on Assets5.15% Debt Debt-to-Equity Ratio0.71 Current Ratio4.17 Quick Ratio2.13 Sales & Book Value Annual Sales$1.79 billion Price / Sales0.39 Cash Flow$8.49 per share Price / Cash Flow1.66 Book Value$30.09 per share Price / Book0.47Miscellaneous Outstanding Shares49,890,000Free Float44,350,000Market Cap$703.45 million OptionableOptionable Beta0.91 Key ExecutivesRobert G. KramerPresident, Chief Executive Officer & DirectorAdam Robert HaveyChief Operating Officer & EVP-Business OperationsRichard Scott LindahlChief Financial Officer, Treasurer & Executive VPSharon M. SolomonChief Information Officer & Senior Vice PresidentChristopher H. CabellChief Medical Officer & Head-Clinical DevelopmentKey CompetitorsIntercept PharmaceuticalsNASDAQ:ICPTAVEO PharmaceuticalsNASDAQ:AVEOInnovivaNASDAQ:INVAVanda PharmaceuticalsNASDAQ:VNDALexicon PharmaceuticalsNASDAQ:LXRXView All CompetitorsInsiders & InstitutionsRobeco Institutional Asset Management B.V.Bought 33,696 shares on 2/7/2023Ownership: 0.068%Envestnet Asset Management Inc.Bought 2,297 shares on 2/7/2023Ownership: 0.032%Shell Asset Management Co.Sold 1,673 shares on 2/7/2023Ownership: 0.017%Gladius Capital Management LPBought 1,531 shares on 2/2/2023Ownership: 0.006%Simplex Trading LLCSold 11,100 shares on 2/2/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions EBS Stock - Frequently Asked Questions Should I buy or sell Emergent BioSolutions stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares. View EBS analyst ratings or view top-rated stocks. What is Emergent BioSolutions' stock price forecast for 2023? 6 brokerages have issued 12 month price objectives for Emergent BioSolutions' stock. Their EBS share price forecasts range from $25.00 to $55.00. On average, they predict the company's share price to reach $36.75 in the next year. This suggests a possible upside of 164.4% from the stock's current price. View analysts price targets for EBS or view top-rated stocks among Wall Street analysts. How have EBS shares performed in 2023? Emergent BioSolutions' stock was trading at $11.81 at the beginning of the year. Since then, EBS shares have increased by 17.7% and is now trading at $13.90. View the best growth stocks for 2023 here. Are investors shorting Emergent BioSolutions? Emergent BioSolutions saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 5,570,000 shares, an increase of 63.3% from the December 31st total of 3,410,000 shares. Based on an average daily volume of 959,600 shares, the short-interest ratio is currently 5.8 days. Approximately 13.7% of the company's stock are sold short. View Emergent BioSolutions' Short Interest. When is Emergent BioSolutions' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023. View our EBS earnings forecast. How can I listen to Emergent BioSolutions' earnings call? Emergent BioSolutions will be holding an earnings conference call on Monday, February 27th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were Emergent BioSolutions' earnings last quarter? Emergent BioSolutions Inc. (NYSE:EBS) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of $2.35 by $2.71. The biopharmaceutical company had revenue of $329 million for the quarter, compared to analysts' expectations of $484.77 million. Emergent BioSolutions had a trailing twelve-month return on equity of 9.52% and a net margin of 3.54%. The firm's revenue was down 14.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.19 earnings per share. What guidance has Emergent BioSolutions issued on next quarter's earnings? Emergent BioSolutions updated its FY 2022 earnings guidance on Friday, January, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.10 billion-$1.12 billion, compared to the consensus revenue estimate of $1.09 billion. What is Bob Kramer's approval rating as Emergent BioSolutions' CEO? 38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees. What other stocks do shareholders of Emergent BioSolutions own? Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV). What is Emergent BioSolutions' stock symbol? Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS." Who are Emergent BioSolutions' major shareholders? Emergent BioSolutions' stock is owned by a variety of institutional and retail investors. Top institutional investors include New York State Common Retirement Fund (0.43%), Nisa Investment Advisors LLC (0.14%), Assenagon Asset Management S.A. (0.12%), Strs Ohio (0.10%), Values First Advisors Inc. (0.07%) and Robeco Institutional Asset Management B.V. (0.07%). Insiders that own company stock include Adam Havey, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Richard S Lindahl, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View institutional ownership trends. How do I buy shares of Emergent BioSolutions? Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Emergent BioSolutions' stock price today? One share of EBS stock can currently be purchased for approximately $13.90. How much money does Emergent BioSolutions make? Emergent BioSolutions (NYSE:EBS) has a market capitalization of $693.47 million and generates $1.79 billion in revenue each year. The biopharmaceutical company earns $230.90 million in net income (profit) each year or $0.78 on an earnings per share basis. How many employees does Emergent BioSolutions have? The company employs 2,416 workers across the globe. How can I contact Emergent BioSolutions? Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The official website for the company is www.emergentbiosolutions.com. The biopharmaceutical company can be reached via phone at (240) 631-3200, via email at burrowsr@ebsi.com, or via fax at 301-795-1899. This page (NYSE:EBS) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.